Skip to content

Author

Hu-Nan Xiao

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Circulating fibroblast growth factor 21 predicts adverse outcomes in patients with pre-heart failure and HFpEF.

It is demonstrated that circulating FGF21 acts as an independent predictor of recurrent heart failure and all-cause death in patients with HFpEF, and may serve as a promising auxiliary biomarker for risk stratification of patients with HFpEF in clinical practice.

Hui-Ying Li, Yu Bao, Hu-Nan Xiao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.